Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02975206 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
A Phase 2 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 484
- Enrollment target
NCT02975206 is a Phase 2 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 484 participants.
The verdict
NCT02975206, a Phase 2 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 484 participants
- Enrollment target
Study Summary
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Interventions
- DRUG Placebo Oral Tablet
- DRUG Serlopitant High Dose
- DRUG Serlopitant Low Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02975206
The ClinicalTrials.gov registry entry for NCT02975206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Oral Tablet is the first listed.
NCT02975206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02975206 about?
NCT02975206 is a clinical study titled "Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis". Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
What is the current status of trial NCT02975206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 484 participants. The study started on 2016-11. Estimated completion is 2018-02-23.
What interventions are being tested in trial NCT02975206?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Serlopitant High Dose (DRUG), Serlopitant Low Dose (DRUG).
Who is sponsoring clinical trial NCT02975206?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.